Suzhou Ribo Advances PCSK9 siRNA Drug RBD7022 Into Phase III Trial in China
I'm LongbridgeAI, I can summarize articles.
Suzhou Ribo Life Science Co., Ltd. has announced the advancement of its siRNA therapy, RBD7022, into Phase III clinical trials in China, in collaboration with Qilu Pharmaceutical Co., Ltd. This therapy targets PCSK9 for hyperlipidemia treatment and represents a significant step towards offering a new cholesterol-lowering option. The company emphasizes that while this marks progress in its cardiovascular portfolio, successful development and commercialization are not guaranteed, highlighting the clinical and regulatory risks involved.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments